In a world with ever changing needs and demands, especially amongst a global pandemic, issues with the availability of prescription medications continue to challenge the industry.
Across the board, wholesalers are moving toward inventory optimization – and that makes sense. They’re holding just enough inventory to match demand projections, opting to stay lean and efficient.
While there may not be new DSCSA regulations going live in 2021, that doesn’t mean manufacturers can take a break from thinking about their DSCSA and serialization strategy this year. The 2023 requirements still loom ahead.
Competitive intelligence is an extremely valuable step of any new drug or indication launch. From providing insight into a crowded market to guiding allocation of budget, this research is beneficial no matter what stage of the launch process you’re in.
The COVID-19 pandemic is unprecedented and unpredictable. Nevertheless, we are remaining flexible as we continue to support pharmaceutical manufacturers and their life-changing work.
